SLC20A2

Across TCGA pan-cancer cohorts, SLC20A2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated SLC20A2 data layer compared with 27 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher SLC20A2 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated SLC20A2 expression acts as an unfavorable survival marker, although some lineages such as LUAD and LSCC show a favorable association.

PDAC, LUAD, and LSCC are the cancer types where SLC20A2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	All	0.408	0.580	.018	14	view →
LUAD	OS	Quartile	II,III,IV	1.000	0.710	.005	12	view →
LSCC	DFS	Median	II,III,IV	1.000	0.830	.003	12	view →
GBM	OS	Quartile	All	0.724	0.306	.001	8	view →
HNSC	DFS	Tertile	III,IV	0.906	0.687	.024	7	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

SLC20A2–PDAC (OS)

Open the PDAC breakdown →